AbbVie has scored a major reduction of damages in a retrial of an AndroGel liability case. After a judge nixed the initial verdict of $150 million and sent the case back for retrial, a jury this week ...

ATLANTA (CN) - A federal judge dismissed the remaining claims in a nearly 10-year-old dispute over competition on AndroGel, a drug that boosts testosterone production. In the 1990s, Unimed ...

AbbVie notched a win late last month in its ongoing battle against thousands of lawsuits that claim AndroGel, a once-blockbuster drug marketed to treat low testosterone in men, causes heart attacks, ...

AbbVie Inc (NYSE:ABBV) has petitioned the U.S. Supreme Court to protect its corporate records, arguing that a lower court ruling threatens the confidentiality of attorney communications. The ...

June 29 (Reuters) - A U.S. judge on Friday found that pharmaceutical company AbbVie Inc used sham litigation to illegally prevent generic versions of testosterone replacement drug AndroGel from ...

Please provide your email address to receive an email when new articles are posted on . In a randomized double blind, placebo-controlled trial with older men assigned either AndroGel 1% (transdermal ...

ABBOTT PARK, Ill., April 29, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved AndroGel® (testosterone gel) 1.62%, a clear, odorless ...

(Reuters) - A U.S. judge on Thursday overturned a $140.1 million verdict against AbbVie Inc in a lawsuit by a man who claimed the company misrepresented the risks of its testosterone replacement drug ...

Thousands of federal lawsuits alleging harm from AbbVie’s AndroGel are on the cusp of being settled, marking the end of a long legal saga about the safety of testosterone therapy and the marketing ...

It might be exaggerating to say that AbbVie—Abbott’s new break-out pharma division—overcame a host of challenges to establish AndroGel as the preeminent product in the low-testosterone category. Or ...